Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356262 | 0.97 | EPHX1 (0.46) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL1089229 | 0.96 | EPHX1 (0.43) | EPHX1TP53KDM4EGMNNLMNA | |
| Hydrochloric Acid SCHEMBL1354672 | 0.94 | KDM4E (0.44) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5200916 | 0.93 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL44016 | 0.93 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL22570753 | 0.93 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL12960418 | 0.93 | — | — | |
| SCHEMBL2139173 | 0.93 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| Hydrochloric Acid SCHEMBL2464621 | 0.90 | KDM4E (0.46) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL20721151 | 0.90 | EPHX1 (0.46) | EPHX1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737823-A2 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2007-01-03 | — | — | EP | claimed |
| WO-2005103002-A2 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-9782407-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| EP-1848430-B1 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-08-02 | — | — | EP | disclosed |
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-9040558-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-05-26 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-8604055-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-12-10 | — | — | US | disclosed |
| WO-2011042145-A1 | WNT PATHWAY ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2011-04-14 | — | — | WO | disclosed |
| EP-1848430-A2 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Reddy US Therapeutics, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
| WO-2006073973-A2 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, DBI | EPHX1 1941/4885TP53 4843/4885KDM4E 1691/4885 |
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, MTTP | EPHX1 1239/4885TP53 4581/4885KDM4E 1933/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | EPHX1 1941/4885TP53 4843/4885KDM4E 1691/4885 |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | CETP, NPC1, LIPC | EPHX1 2034/4885TP53 4679/4885KDM4E 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.